---
document_datetime: 2025-12-02 05:23:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/jevtana.html
document_name: jevtana.html
version: success
processing_time: 0.1307775
conversion_datetime: 2025-12-27 21:22:14.18327
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Jevtana

[RSS](/en/individual-human-medicine.xml/66311)

##### Authorised

This medicine is authorised for use in the European Union

cabazitaxel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79754)
- [More information on Jevtana](#more-information-on-jevtana-664)
- [More information on Jevtana](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Jevtana. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Jevtana.

Expand section

Collapse section

## What is Jevtana and what is it used for?

Jevtana is a cancer medicine used to treat men with metastatic castration-resistant prostate cancer. This is cancer that affects the prostate gland in men that produces the liquid in semen. Jevtana is used when the cancer has spread to other parts of the body (metastatic) despite treatments to prevent the production of testosterone or after surgical removal of the testes (castration). Jevtana is used in combination with prednisone or prednisolone (anti-inflammatory medicines) in patients who have previously been treated with docetaxel (another cancer medicine).

Jevtana contains the active substance cabazitaxel.

## How is Jevtana used?

Jevtana can only be obtained with a prescription and should only be used in units specialising in chemotherapy (medicines to treat cancer) under the supervision of a doctor experienced in the use of chemotherapy.

Jevtana is available as a concentrate and a solvent to be made up into a solution for infusion (drip) into a vein. It is given once every three weeks as an infusion lasting one hour, at a dose of 25 mg per square metre body surface area (calculated using the patient's weight and height). It is given in combination with prednisone or prednisolone, taken daily throughout treatment.

The dose of Jevtana should be reduced or treatment stopped if the patient has certain side effects. The doses should also be reduced in patients with mildly or moderately reduced liver function.

Before receiving Jevtana infusions, patients should first be given medicines to prevent allergic reactions and medicines to prevent vomiting.

For more information, see the package leaflet.

## How does Jevtana work?

The active substance in Jevtana, cabazitaxel, belongs to the group of cancer medicines known as 'taxanes'. Cabazitaxel works by blocking the ability of cancer cells to break down their internal 'skeleton' that allows them to divide and multiply. With their skeleton still in place, the cells cannot divide and they eventually die. Jevtana also affects non-cancer cells, such as blood and nerve cells, which can cause side effects.

## What benefits of Jevtana have been shown in studies?

Jevtana prolonged overall survival (the average length of time the patients lived) in one main study involving 755 men with metastatic castration-resistant prostate cancer who had previously been treated with docetaxel. The effects of Jevtana were compared with another cancer medicine, mitoxantrone. Both medicines were given in combination with prednisone or prednisolone. The average overall survival for patients treated with Jevtana was 15.1 months compared with 12.7 months for patients given mitoxantrone.

## What are the risks associated with Jevtana?

The most common side effects with Jevtana (seen in more than 1 patient in 10) include anaemia (low red blood cell counts), leucopenia (low white blood cell counts), neutropenia (low counts of neutrophils, a type of white blood cell), thrombocytopenia (low blood platelet counts) and diarrhoea. Some of these effects were severe. For the full list of all side effects reported with Jevtana, see the package leaflet.

Jevtana must not be used in people who are hypersensitive (allergic) to cabazitaxel, to any other taxane, or to any of the other ingredients. It must not be given to patients whose blood neutrophil count is below 1,500/mm 3 , who have severely reduced liver function or who recently received or are about to receive a yellow fever vaccine.

## Why has Jevtana been approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that the ability of Jevtana to prolong overall survival in castration-resistant metastatic prostate cancer patients was clinically important. It decided that Jevtana's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Jevtana?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jevtana have been included in the summary of product characteristics and the package leaflet.

## Other information about Jevtana

The European Commission granted a marketing authorisation valid throughout the European Union for Jevtana on 17 March 2011.

For more information about treatment with Jevtana, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Jevtana : EPAR - Summary for the public

English (EN) (78.05 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 05/05/2017

[View](/en/documents/overview/jevtana-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-934)

български (BG) (101.56 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/bg/documents/overview/jevtana-epar-summary-public_bg.pdf)

español (ES) (75.86 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/es/documents/overview/jevtana-epar-summary-public_es.pdf)

čeština (CS) (100.07 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/cs/documents/overview/jevtana-epar-summary-public_cs.pdf)

dansk (DA) (75.03 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/da/documents/overview/jevtana-epar-summary-public_da.pdf)

Deutsch (DE) (76.78 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/de/documents/overview/jevtana-epar-summary-public_de.pdf)

eesti keel (ET) (73.58 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/et/documents/overview/jevtana-epar-summary-public_et.pdf)

ελληνικά (EL) (102.11 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/el/documents/overview/jevtana-epar-summary-public_el.pdf)

français (FR) (76.61 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/fr/documents/overview/jevtana-epar-summary-public_fr.pdf)

hrvatski (HR) (93.53 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/hr/documents/overview/jevtana-epar-summary-public_hr.pdf)

italiano (IT) (75.23 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/it/documents/overview/jevtana-epar-summary-public_it.pdf)

latviešu valoda (LV) (96.44 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/lv/documents/overview/jevtana-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.21 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/lt/documents/overview/jevtana-epar-summary-public_lt.pdf)

magyar (HU) (93.84 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/hu/documents/overview/jevtana-epar-summary-public_hu.pdf)

Malti (MT) (101.43 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/mt/documents/overview/jevtana-epar-summary-public_mt.pdf)

Nederlands (NL) (75.59 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/nl/documents/overview/jevtana-epar-summary-public_nl.pdf)

polski (PL) (101.69 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/pl/documents/overview/jevtana-epar-summary-public_pl.pdf)

português (PT) (76.15 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/pt/documents/overview/jevtana-epar-summary-public_pt.pdf)

română (RO) (96.36 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/ro/documents/overview/jevtana-epar-summary-public_ro.pdf)

slovenčina (SK) (99.05 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/sk/documents/overview/jevtana-epar-summary-public_sk.pdf)

slovenščina (SL) (93.87 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/sl/documents/overview/jevtana-epar-summary-public_sl.pdf)

Suomi (FI) (74.9 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/fi/documents/overview/jevtana-epar-summary-public_fi.pdf)

svenska (SV) (75.34 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/05/2017

[View](/sv/documents/overview/jevtana-epar-summary-public_sv.pdf)

Jevtana : EPAR - Risk-management-plan summary

English (EN) (38.55 KB - PDF)

**First published:** 17/12/2020

[View](/en/documents/rmp-summary/jevtana-epar-risk-management-plan-summary_en.pdf)

## Product information

Jevtana : EPAR - Product Information

English (EN) (989.32 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 30/09/2025

[View](/en/documents/product-information/jevtana-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-169)

български (BG) (1.02 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/bg/documents/product-information/jevtana-epar-product-information_bg.pdf)

español (ES) (488.71 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/es/documents/product-information/jevtana-epar-product-information_es.pdf)

čeština (CS) (909.18 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/cs/documents/product-information/jevtana-epar-product-information_cs.pdf)

dansk (DA) (785.95 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/da/documents/product-information/jevtana-epar-product-information_da.pdf)

Deutsch (DE) (901.51 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/de/documents/product-information/jevtana-epar-product-information_de.pdf)

eesti keel (ET) (547.36 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/et/documents/product-information/jevtana-epar-product-information_et.pdf)

ελληνικά (EL) (852.3 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/el/documents/product-information/jevtana-epar-product-information_el.pdf)

français (FR) (861.87 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/fr/documents/product-information/jevtana-epar-product-information_fr.pdf)

hrvatski (HR) (744.09 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/hr/documents/product-information/jevtana-epar-product-information_hr.pdf)

íslenska (IS) (746.4 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/is/documents/product-information/jevtana-epar-product-information_is.pdf)

italiano (IT) (636.85 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/it/documents/product-information/jevtana-epar-product-information_it.pdf)

latviešu valoda (LV) (741.06 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/lv/documents/product-information/jevtana-epar-product-information_lv.pdf)

lietuvių kalba (LT) (705.2 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/lt/documents/product-information/jevtana-epar-product-information_lt.pdf)

magyar (HU) (767.4 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/hu/documents/product-information/jevtana-epar-product-information_hu.pdf)

Malti (MT) (792.35 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/mt/documents/product-information/jevtana-epar-product-information_mt.pdf)

Nederlands (NL) (1000.39 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/nl/documents/product-information/jevtana-epar-product-information_nl.pdf)

norsk (NO) (853.43 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/no/documents/product-information/jevtana-epar-product-information_no.pdf)

polski (PL) (710.71 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/pl/documents/product-information/jevtana-epar-product-information_pl.pdf)

português (PT) (644.71 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/pt/documents/product-information/jevtana-epar-product-information_pt.pdf)

română (RO) (822.3 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/ro/documents/product-information/jevtana-epar-product-information_ro.pdf)

slovenčina (SK) (861.92 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/sk/documents/product-information/jevtana-epar-product-information_sk.pdf)

slovenščina (SL) (751.22 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/sl/documents/product-information/jevtana-epar-product-information_sl.pdf)

Suomi (FI) (1.12 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/fi/documents/product-information/jevtana-epar-product-information_fi.pdf)

svenska (SV) (1.09 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

30/09/2025

[View](/sv/documents/product-information/jevtana-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000295586 30/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Jevtana : EPAR - All Authorised presentations

English (EN) (14.27 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 05/04/2011

[View](/en/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-939)

български (BG) (83.45 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/bg/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.8 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/es/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_es.pdf)

čeština (CS) (84.44 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/cs/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.41 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/da/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.99 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/de/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.16 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/et/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (78.48 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/el/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_el.pdf)

français (FR) (24.06 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/fr/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.7 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/hr/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.52 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/is/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.71 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/it/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (84.92 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/lv/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.77 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/lt/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (48.44 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/hu/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (84.44 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/mt/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.08 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/nl/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.25 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/no/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_no.pdf)

polski (PL) (95.14 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/pl/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.92 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/pt/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_pt.pdf)

română (RO) (87.56 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/ro/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (84.52 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/sk/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.49 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/sl/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.44 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/fi/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.06 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

05/04/2011

[View](/sv/documents/all-authorised-presentations/jevtana-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Jevtana Active substance cabazitaxel International non-proprietary name (INN) or common name cabazitaxel Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L01CD

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

## Authorisation details

EMA product number EMEA/H/C/002018 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Opinion adopted 20/01/2011 Marketing authorisation issued 17/03/2011 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Jevtana : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.3 KB - PDF)

**First published:** 30/09/2025

[View](/en/documents/procedural-steps-after/jevtana-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Jevtana : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (199.35 KB - PDF)

**First published:** 25/11/2011

**Last updated:** 03/09/2024

[View](/en/documents/procedural-steps-after/jevtana-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Jevtana-PSUSA-00000476-202106 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/128719/2023

English (EN) (100.04 KB - PDF)

**First published:** 17/03/2023

[View](/en/documents/scientific-conclusion/jevtana-psusa-00000476-202106-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Jevtana-PSUSA-00000476-201506 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/148593/2016

English (EN) (69.48 KB - PDF)

**First published:** 11/08/2016

**Last updated:** 11/08/2016

[View](/en/documents/scientific-conclusion/jevtana-psusa-00000476-201506-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Jevtana-H-C-2018-PSUV-0023 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/657437/2015

English (EN) (69.81 KB - PDF)

**First published:** 05/10/2015

**Last updated:** 05/10/2015

[View](/en/documents/scientific-conclusion/jevtana-h-c-2018-psuv-0023-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Jevtana : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/66633/2011

English (EN) (947.92 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 13/04/2012

[View](/en/documents/assessment-report/jevtana-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Jevtana

Adopted

Reference Number: EMA/26276/2011

English (EN) (113.16 KB - PDF)

**First published:** 21/01/2011

**Last updated:** 21/01/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-jevtana_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Jevtana : EPAR - Product information - tracked changes

English (EN) (1.17 MB - DOCX)

**First published:** 30/09/2025

[View](/en/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-928)

български (BG) (1.68 MB - DOC)

**First published:**

30/09/2025

[View](/bg/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_bg.doc)

español (ES) (1.6 MB - DOC)

**First published:**

30/09/2025

[View](/es/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_es.doc)

čeština (CS) (1.58 MB - DOC)

**First published:**

30/09/2025

[View](/cs/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (1.6 MB - DOC)

**First published:**

30/09/2025

[View](/da/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (1.99 MB - DOCX)

**First published:**

30/09/2025

[View](/de/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (1.61 MB - DOC)

**First published:**

30/09/2025

[View](/et/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (946.56 KB - DOCX)

**First published:**

30/09/2025

[View](/el/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_el.docx)

français (FR) (1.39 MB - DOC)

**First published:**

30/09/2025

[View](/fr/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (1.86 MB - DOC)

**First published:**

30/09/2025

[View](/hr/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (727.97 KB - DOCX)

**First published:**

30/09/2025

[View](/is/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_is.docx)

italiano (IT) (3.06 MB - DOCX)

**First published:**

30/09/2025

[View](/it/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (2.22 MB - DOCX)

**First published:**

30/09/2025

[View](/lv/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (1.68 MB - DOC)

**First published:**

30/09/2025

[View](/lt/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (1.76 MB - DOC)

**First published:**

30/09/2025

[View](/hu/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (2.52 MB - DOCX)

**First published:**

30/09/2025

[View](/mt/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (2.6 MB - DOCX)

**First published:**

30/09/2025

[View](/nl/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (4.34 MB - DOC)

**First published:**

30/09/2025

[View](/no/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_no.doc)

polski (PL) (764.26 KB - DOCX)

**First published:**

30/09/2025

[View](/pl/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_pl.docx)

português (PT) (1.05 MB - DOCX)

**First published:**

30/09/2025

[View](/pt/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_pt.docx)

română (RO) (1.79 MB - DOC)

**First published:**

30/09/2025

[View](/ro/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_ro.doc)

slovenčina (SK) (1.71 MB - DOC)

**First published:**

30/09/2025

[View](/sk/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (1.38 MB - DOC)

**First published:**

30/09/2025

[View](/sl/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (1.74 MB - DOC)

**First published:**

30/09/2025

[View](/fi/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (1.59 MB - DOC)

**First published:**

30/09/2025

[View](/sv/documents/product-information-tracked-changes/jevtana-epar-product-information-tracked-changes_sv.doc)

#### More information on Jevtana

- [The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the Committee for Medicinal Products for Human Use](http://theoncologist.alphamedpress.org/content/17/4/543.long)

#### More information on Jevtana

- [Cabazitaxel Accord - medication error](/en/medicines/human/medication-error/cabazitaxel-accord)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/09/2025

## Share this page

[Back to top](#main-content)